EGFR and melanoma: The activation of the RAS signaling pathway by EGFR in cancer is well known [41]; however, in CM, there is limited information available on the role of this tyrosine kinase receptor (TKR), apart from its expression in melanocytic nevi and some melanomas [42,43,44,45].